KYNB
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Graham Number and Intrinsic Value are unavailable due to negative earnings and equity.
- Negative P/B ratio
- P/S ratio of 4.51 is high for a company with shrinking revenue
Growth metrics are overwhelmingly negative.
- High analyst target price ($43)
- Revenue growth -59.30%
- Negative EPS growth trends
Long-term historical performance is catastrophic.
- 1-year return +10.3%
- 5-year return -98.6%
- 3-year return -98.5%
Piotroski score indicates extreme weakness; Altman Z-Score not provided but implied distress.
- Current Ratio 3.39
- Piotroski F-Score 1/9
- Debt/Equity 4.37
- Negative ROA
Non-dividend paying biotech.
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for KYNB and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
KYNB
Kyntra Bio, Inc.
Primary
|
-98.6% | -98.5% | +10.3% | -32.0% | +0.7% | +2.3% |
|
BTAI
BioXcel Therapeutics, Inc.
Peer
|
-99.8% | -99.6% | -30.1% | -56.4% | -37.0% | -18.7% |
|
AYTU
Aytu BioPharma, Inc.
Peer
|
-98.4% | -24.2% | +61.7% | +2.7% | +6.7% | +1.5% |
|
EKSO
Ekso Bionics Holdings, Inc.
Peer
|
-91.1% | -64.0% | +54.0% | +66.6% | -27.2% | -18.0% |
|
ICCM
IceCure Medical Ltd
Peer
|
-97.0% | -71.2% | -71.9% | -62.9% | -51.7% | +7.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
KYNB
Kyntra Bio, Inc.
|
BEARISH | $29.02M | - | -% | 2848.6% | $7.17 | |
|
BTAI
BioXcel Therapeutics, Inc.
|
BEARISH | $29.51M | - | -% | -% | $1.09 | Compare |
|
AYTU
Aytu BioPharma, Inc.
|
NEUTRAL | $27.51M | - | -50.2% | -20.5% | $2.7 | Compare |
|
EKSO
Ekso Bionics Holdings, Inc.
|
BEARISH | $31.11M | - | -107.6% | -91.4% | $8.73 | Compare |
|
ICCM
IceCure Medical Ltd
|
BEARISH | $26.25M | - | -188.8% | -% | $0.32 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-17 | WETTIG THANE | Chief Executive Officer | Purchase | 3,700 | $33,750 |
Past News Coverage
Recent headlines mentioning KYNB from our newsroom.